Pinpoint Med

Pinpoint Therapeutics is a precision oncology company focused on developing a new class of autophagy inhibitors to treat drug-resistant cancers. The company's lead research centers on targeting Palmitoyl-protein thioesterase 1 (PPT1), a critical regulator of lysosomal function and autophagy that is frequently upregulated in various malignancies. By utilizing dimeric chloroquine derivatives, Pinpoint aims to overcome the limitations of traditional autophagy inhibitors like hydroxychloroquine, providing more potent and selective therapeutic options. Founded as a spin-out from the University of Pennsylvania, the company is advancing its pipeline toward IND-enabling studies for indications including melanoma and pancreatic cancer.